Real-world experience of adding placental histopathology studies into perinatal clinical trials

T. Yee Khong*, Sanne J. Gordijn, Mirthe H. Schoots, Wessel Ganzevoort, Katie M. Groom, Suzette Coat, William M. Hague

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
111 Downloads (Pure)

Abstract

Addition of placental histopathology studies to obstetric trials is likely to be cost-effective and may reveal structural changes suggestive of functional dysfunction to explain the success or failure of a clinical intervention. We share our recent experience in adding placental pathological examination to two clinical trials, retrospectively in one and at the outset in the other, so that other clinical trial investigators may benefit from it. The practical issues can be summarised as being regulatory and ethical, operational and reporting. Prospective inclusion of placental pathological examination as part of a clinical trial protocol is easier than retrospective, and is facilitated by fully-costed funding.

Original languageEnglish
Pages (from-to)26-28
Number of pages3
JournalPlacenta
Volume136
DOIs
Publication statusPublished - May-2023

Keywords

  • Lessons
  • Multicentre
  • Multinational
  • Pathology
  • Placenta
  • Trial

Fingerprint

Dive into the research topics of 'Real-world experience of adding placental histopathology studies into perinatal clinical trials'. Together they form a unique fingerprint.

Cite this